Takasita GMS, Guerrero JM, Cuenca FLA, Minjarez ÁR, Sahagún FJE

Language: Spanish
References: 15
Page: 218-222
PDF size: 194.49 Kb.

ABSTRACT

The osteonecrosis of the jaw secondary to the administration of bisphosphonates consists of exposed and necrotic alveolar bone, this condition can occur in patients with prostate cancer treated on the basis of bisphosphonates. To qualify as osteonecrosis, it is required the presence of lesions associated with bisphosphonates, active for a minimum of eight weeks without healing or improvement. The differential diagnosis includes mainly osteoradionecrosis, which can be discarded by history. There is no consensus on which is the best treatment; aggressive bone removal and handling ozone have been used with poor results, the most used is the aggressive removal of necrotic alveolar bone. We report a case successfully managed with removal of necrotic tissue infiltration, plus collagenpolyvinylpyrrolidone.

REFERENCES

1. Markose G, Mackenzie FR, Currie WJ, Hislop WS. Bisphosphonate osteonecrosis: a protocol for surgical management. Br J Oral Maxillofac Surg 2009;47:294-297.

2. Naveau A, Naveau B. Osteonecrosis of the jaw in patients taking bisphosphonates. Joint Bone Spine 2006;73:7-9.

3. Diego R, D’Orto O, Pagani D, Agazzi A, et al. Bisphosphonate- associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103(3):e1-5.

4. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, et al. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(1):14-21.

5. Mücke T, Haarmann S, Wolff KD, Hölzle F. Bisphosphonate related osteonecrosis of the jaws treated by surgical resection and immediate osseous microvascular reconstruction. J Craniomaxillofac Surg 2009;37(5):291-297.

6. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonate- induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006;35(7):588- 593.

7. Gallego L, Junquera L. Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws. Br J Oral Maxillofac Surg 2009;47(1):67-68.

8. De Hoyos Garza A, Aguilar EA, Richards GC. Ileocolonic ulcer treated by endoscopic application of collagen-polyvinylpyrrolidone. Can J Gastroenterol 2007;21(8):513-515.

9. Furuzawa CCZ, García ARL, Furuzawa CJ. Estudio piloto sobre la eficacia del uso de la colágena-polivinilpirrolidona (Clg-PVP) en la regeneración ósea en cirugía endodóncica. Revista Odontológica Mexicana 2005;9:191-196.

10. Rodríguez-Calderón R, Furuzawa-Carballeda J, Corchado A, Krötzsch E. Collagen-polyvinylpyrrolidone promotes human wound healing through cytokine down modulation. Wound Rep Reg 2001;9(2):166.

11. Krötzsch-Gómez FE, Furuzawa-Carballeda J, Reyes-Márquez R, Quiróz-Hernández E, Díaz de León L. Cytokine expression is downregulated by collagen-polyvinylpyrrolidone in hypertrophic scars. J Invest Dermatol 1998;111(5):828- 834.

12. Furuzawa-Carballeda J, Krötzsch E, Barile-Fabris L, Alcalá M, Espinosa-Morales R. Subcutaneous administration of collagen-polyvinylpyrrolidone down regulates IL-1beta, TNF-alpha, TGF-beta1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions. Clin Exp Dermatol 2005;30(1):83- 86.

13. Zerón HM, Krötzsch Gómez FE, Muńoz RE. Pressure ulcers: a pilot study for treatment with collagen polyvinylpyrrolidone. Int J Dermatol 2007;46(3):314-317.

14. Suárez Colín A, Salgado RM, Apis Hernández AMZ, Krötzsch E. Inducción del tejido de granulación por pasta de Lassar vs colágena-polivinilpirrolidona en úlceras por insuficiencia venosa. Cirugía Plástica 2004;14:5-13.

15. Bermúdez-Hickey R, Nesme-Ávila W, Ruiz-Flores L, Suárez E. Tratamiento de la pseudoartrosis de tibia con colágenopolivinilpirrolidona. Rev Mex Ortop Trauma 1999;13:148- 151.